XML 18 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Document and Entity Information - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2022
Mar. 15, 2023
Jun. 30, 2022
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Period End Date Dec. 31, 2022    
Document Fiscal Year Focus 2022    
Document Fiscal Period Focus FY    
Entity Registrant Name MiNK Therapeutics, Inc.    
Entity Central Index Key 0001840229    
Entity Current Reporting Status Yes    
Entity Voluntary Filers No    
Entity Interactive Data Current Yes    
Current Fiscal Year End Date --12-31    
Entity Filer Category Non-accelerated Filer    
Entity Well-known Seasoned Issuer No    
Entity Public Float     $ 6.6
Entity Common Stock, Shares Outstanding   33,910,688  
Entity Shell Company false    
Entity Small Business true    
Entity Emerging Growth Company true    
Title of 12(b) Security Common Stock, par value $0.00001 per share    
Trading Symbol INKT    
Security Exchange Name NASDAQ    
Entity File Number 001-40908    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 82-2142067    
Entity Address, Address Line One 149 Fifth Avenue    
Entity Address, Address Line Two Suite 500    
Entity Address, City or Town New York    
Entity Address, State or Province NY    
Entity Address, Postal Zip Code 10010    
City Area Code 212    
Local Phone Number 994-8250    
Document Annual Report true    
Document Transition Report false    
ICFR Auditor Attestation Flag false    
Entity Ex Transition Period false    
Auditor Name KPMG LLP    
Auditor Location Boston, Massachusetts    
Auditor Firm ID 185    
Documents Incorporated by Reference

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the Registrant’s Definitive Proxy Statement relating to the 2023 Annual Meeting of Stockholders, which the registrant intends to file with the Securities and Exchange Commission pursuant to Regulation 14A within 120 days after the end of the registrant’s fiscal year ended December 31, 2022, are incorporated by reference into Part III of this Report.